Ehsanullah Syed, Hasan Syed, Polani Faran S, Rashid Syeda Zarmeena, Ahmed Syed Ijlal
Medicine, Washington University School of Medicine, St. Louis, USA.
Oncology, Washington University School of Medicine, St. Louis, USA.
Cureus. 2022 Feb 24;14(2):e22584. doi: 10.7759/cureus.22584. eCollection 2022 Feb.
Immunotherapy is a biological therapy that helps the body's immune system to fight against cancer cells. The Food and Drug Administration (FDA) approved the first immune checkpoint inhibitor in 2011. Since 2011, many immune checkpoint inhibitors have been approved. Programmed cell death 1 (PD-1) inhibitors are now commonly used in multiple malignancies due to their remarkable response. Thus, immune-related adverse events are now coming into the limelight due to the increasing use of PD-1 inhibitors. Here, we present a case of a 54-year-old female with non-small cell lung cancers (NSCLC) treated with pembrolizumab and later presented with severe neurotoxicity.
免疫疗法是一种生物疗法，可帮助人体免疫系统对抗癌细胞。美国食品药品监督管理局（FDA）于2011年批准了首个免疫检查点抑制剂。自2011年以来，许多免疫检查点抑制剂已获批准。程序性细胞死亡1（PD-1）抑制剂由于其显著疗效，目前常用于多种恶性肿瘤的治疗。因此，随着PD-1抑制剂使用的增加，免疫相关不良事件如今备受关注。在此，我们报告一例54岁非小细胞肺癌（NSCLC）女性患者，其接受帕博利珠单抗治疗后出现严重神经毒性。
